Literature DB >> 30700419

Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.

Joshua Muia1, Jian Zhu1, Suellen C Greco2, Karen Vanhoorelbeke3, Garima Gupta1, Lisa A Westfield1, J Evan Sadler1,4.   

Abstract

The metalloprotease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats member 13) prevents microvascular thrombosis by cleaving von Willebrand factor (VWF) within platelet-rich thrombi, and cleavage depends on allosteric activation of ADAMTS13 by the substrate VWF. Human ADAMTS13 has a short propeptide, metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domains (proximal domains), followed by 7 T and 2 CUB (complement components C1r and C1s, sea urchin protein Uegf, and bone morphogenetic protein-1) domains (distal domains). Distal domains inhibit the catalytic proximal domains; binding of distal T8-CUB domains to the VWF D4 domain relieves autoinhibition and promotes cleavage of the nearby VWF A2 domain. However, the role of specific ADAMTS13 distal domains in this allosteric mechanism is not established. Assays of plasma ADAMTS13 from 20 placental mammals, birds, and amphibians show that allosteric regulation is broadly conserved, and phylogenetic analysis of 264 vertebrates shows the long propeptide, T3, T4, T6, and T6a domains have been deleted several times in placental mammals, birds, and fish. Notably, pigeon ADAMTS13 has only 3 distal T domains but was activated normally by human VWF D4 and cleaved VWF multimers, preferentially under fluid shear stress. Human ADAMTS13 constructed to resemble pigeon ADAMTS13 retained normal allosteric regulation and shear-dependent cleavage of VWF. Thus, the T3-T6 domains of human ADAMTS13 are dispensable. Conversely, deletion of T7 or T8 abolished allosteric activation. For most species, some sequence changes in the VWF substrate can markedly increase the rate of cleavage, suggesting that ADAMTS13 and VWF have not evolved to be optimal enzyme-substrate pairs. These properties may reflect evolutionary pressure to balance the risk for VWF-dependent bleeding and thrombosis.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30700419      PMCID: PMC6484387          DOI: 10.1182/blood-2018-11-886275

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

Authors:  Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-06-05       Impact factor: 5.157

2.  Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.

Authors:  Rana Grillberger; Veronica C Casina; Peter L Turecek; X Long Zheng; Hanspeter Rottensteiner; Friedrich Scheiflinger
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

3.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

4.  Cleavage of the ADAMTS13 propeptide is not required for protease activity.

Authors:  Elaine M Majerus; Xinglong Zheng; Elodee A Tuley; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-09-15       Impact factor: 5.157

5.  Multi-step binding of ADAMTS-13 to von Willebrand factor.

Authors:  H B Feys; P J Anderson; K Vanhoorelbeke; E M Majerus; J E Sadler
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

6.  Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity.

Authors:  Weiqiang Gao; Patricia J Anderson; J Evan Sadler
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

7.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

8.  An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.

Authors:  Wouter Pos; James T B Crawley; Rob Fijnheer; Jan Voorberg; David A Lane; Brenda M Luken
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

9.  Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.

Authors:  Colin A Kretz; Manhong Dai; Onuralp Soylemez; Andrew Yee; Karl C Desch; David Siemieniak; Kärt Tomberg; Fyodor A Kondrashov; Fan Meng; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

10.  A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor.

Authors:  Kieron South; Marta O Freitas; David A Lane
Journal:  J Biol Chem       Date:  2017-02-16       Impact factor: 5.157

View more
  10 in total

1.  Hairpin and allosteric regulation in ADAMTS13.

Authors:  Dominic W Chung
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Exploring the "minimal" structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering.

Authors:  Jian Zhu; Joshua Muia; Garima Gupta; Lisa A Westfield; Karen Vanhoorelbeke; Niraj H Tolia; J Evan Sadler
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

Review 4.  ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.

Authors:  Konstantine Halkidis; X Long Zheng
Journal:  J Thromb Haemost       Date:  2022-08-03       Impact factor: 16.036

5.  Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function.

Authors:  An-Sofie Schelpe; Anastasis Petri; Elien Roose; Inge Pareyn; Hans Deckmyn; Simon F De Meyer; James T B Crawley; Karen Vanhoorelbeke
Journal:  Blood Adv       Date:  2020-03-24

6.  A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.

Authors:  Konstantine Halkidis; Don L Siegel; X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-05-11       Impact factor: 16.036

7.  Domain-specific mechanical modulation of VWF-ADAMTS13 interaction.

Authors:  Zhenhai Li; Jiangguo Lin; Todd Sulchek; Miguel A Cruz; Jianhua Wu; Jing-Fei Dong; Cheng Zhu
Journal:  Mol Biol Cell       Date:  2019-05-08       Impact factor: 4.138

8.  Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.

Authors:  H J Kim; Y Xu; A Petri; K Vanhoorelbeke; J T B Crawley; J Emsley
Journal:  Sci Adv       Date:  2021-04-16       Impact factor: 14.136

9.  Cloning, Expression and Inhibitory Effects on Lewis Lung Carcinoma Cells of rAj-Tspin from Sea Cucumber (Apostichopus japonicus).

Authors:  Rong Qiao; Rong Xiao; Zhong Chen; Jingwei Jiang; Chenghua Yuan; Shuxiang Ning; Jihong Wang; Zunchun Zhou
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

10.  Crystal structure and substrate-induced activation of ADAMTS13.

Authors:  Anastasis Petri; Hyo Jung Kim; Yaoxian Xu; Rens de Groot; Chan Li; Aline Vandenbulcke; Karen Vanhoorelbeke; Jonas Emsley; James T B Crawley
Journal:  Nat Commun       Date:  2019-08-22       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.